Wen Xue

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7084122/wen-xue-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

48 papers	6,400 citations	27 h-index	57 g-index
57 ext. papers	7,730 ext. citations	20.4 avg, IF	5.51 L-index

#	Paper	IF	Citations
48	Genome-wide detection of CRISPR editing in vivo using GUIDE-tag.. *Nature Communications*, **2022**, 13, 437	17.4	1
47	A flexible split prime editor using truncated reverse transcriptase improves dual AAV delivery in mouse liver.. *Molecular Therapy*, **2022**,	11.7	2
46	Deletion and replacement of long genomic sequences using prime editing. *Nature Biotechnology*, **2021**,	44.5	13
45	Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo. *Nature Communications*, **2021**, 12, 6267	17.4	5
44	Targeting the De Novo Purine Synthesis Pathway Through Adenylosuccinate Lyase Depletion Impairs Liver Cancer Growth by Perturbing Mitochondrial Function. *Hepatology*, **2021**, 74, 233-247	11.2	3
43	Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice. *Nature Communications*, **2021**, 12, 2121	17.4	45
42	The NIH Somatic Cell Genome Editing program. *Nature*, **2021**, 592, 195-204	50.4	21
41	YAP1 Withdrawal in Hepatoblastoma Drives Therapeutic Differentiation of Tumor Cells to Functional Hepatocyte-Like Cells. *Hepatology*, **2021**, 73, 1011-1027	11.2	6
40	Leveraging the Treg-intrinsic CTLA4-PKC signaling pathway for cancer immunotherapy **2021**, 9,		1
39	Comprehensive identification of alternative back-splicing in human tissue transcriptomes. *Nucleic Acids Research*, **2020**, 48, 1779-1789	20.1	22
38	Advances in CRISPR/Cas-based Gene Therapy in Human Genetic Diseases. *Theranostics*, **2020**, 10, 4374-4382	12.1	38
37	Chemical modifications of adenine base editor mRNA and guide RNA expand its application scope. *Nature Communications*, **2020**, 11, 1979	17.4	31
36	Adenine base editing in an adult mouse model of tyrosinaemia. *Nature Biomedical Engineering*, **2020**, 4, 125-130	19	86
35	Depletion of TRRAP Induces p53-Independent Senescence in Liver Cancer by Down-Regulating Mitotic Genes. *Hepatology*, **2020**, 71, 275-290	11.2	24
34	Tissue-restricted genome editing in vivo specified by microRNA-repressible anti-CRISPR proteins. *Rna*, **2019**, 25, 1421-1431	5.8	35
33	CRISPR-Cas: a tool for cancer research and therapeutics. *Nature Reviews Clinical Oncology*, **2019**, 16, 281-295	19.4	83
32	CRISPR-SONIC: targeted somatic oncogene knock-in enables rapid in vivo cancer modeling. *Genome Medicine*, **2019**, 11, 21	14.4	4

31	Targeted Metabolomics Identifies the Cytochrome P450 Monooxygenase Eicosanoid Pathway as a Novel Therapeutic Target of Colon Tumorigenesis. *Cancer Research*, **2019**, 79, 1822-1830	10.1	29
30	Real-time imaging of integrin β4 dynamics using a reporter cell line generated by Crispr/Cas9 genome editing. *Journal of Cell Science*, **2019**, 132,	5.3	4
29	A Compact, High-Accuracy Cas9 with a Dinucleotide PAM for In Vivo Genome Editing. *Molecular Cell* , **2019**, 73, 714-726.e4	17.6	85
28	CRISPR-Cas-related technologies in basic and translational liver research. *Nature Reviews Gastroenterology and Hepatology*, **2018**, 15, 251-252	24.2	8
27	Partial DNA-guided Cas9 enables genome editing with reduced off-target activity. *Nature Chemical Biology*, **2018**, 14, 311-316	11.7	140
26	In Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency. *Human Gene Therapy*, **2018**, 29, 853-860	4.8	40
25	Cas9-mediated allelic exchange repairs compound heterozygous recessive mutations in mice. *Nature Biotechnology*, **2018**, 36, 839-842	44.5	23
24	Understanding and repurposing CRISPR-mediated alternative splicing. *Genome Biology*, **2018**, 19, 184	18.3	5
23	All-in-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivo. *Genome Biology*, **2018**, 19, 137	18.3	58
22	The temporal landscape of recursive splicing during Pol II transcription elongation in human cells. *PLoS Genetics*, **2018**, 14, e1007579	6	9
21	CRISPR/Cas9-mediated genome editing induces exon skipping by alternative splicing or exon deletion. *Genome Biology*, **2017**, 18, 108	18.3	103
20	Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 3648-3653	11.5	24
19	Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. *Gastroenterology*, **2017**, 152, 1161-1173.e1	13.3	63
18	Oncogenic Activation of the RNA Binding Protein NELFE and MYC Signaling in Hepatocellular Carcinoma. *Cancer Cell*, **2017**, 32, 101-114.e8	24.3	83
17	Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. *Nature Biotechnology*, **2017**, 35, 1179-1187	44.5	255
16	A Modular Assembly Platform for Rapid Generation of DNA Constructs. *Scientific Reports*, **2016**, 6, 16836	4.9	34
15	RNAi-nanoparticulate manipulation of gene expression as a new functional genomics tool in the liver. *Journal of Hepatology*, **2016**, 64, 899-907	13.4	9
14	Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. *Nature Biotechnology*, **2016**, 34, 328-33	44.5	610

13	Genomic Amplifications Cause False Positives in CRISPR Screens. *Cancer Discovery*, **2016**, 6, 824-6	24.4	8
12	A versatile reporter system for CRISPR-mediated chromosomal rearrangements. *Genome Biology*, **2015**, 16, 111	18.3	45
11	Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses. *Human Gene Therapy*, **2015**, 26, 432-42	4.8	226
10	Precision cancer mouse models through genome editing with CRISPR-Cas9. *Genome Medicine*, **2015**, 7, 53	14.4	61
9	Rapid modelling of cooperating genetic events in cancer through somatic genome editing. *Nature*, **2014**, 516, 428-31	50.4	278
8	Small RNA combination therapy for lung cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, E3553-61	11.5	177
7	CRISPR-mediated direct mutation of cancer genes in the mouse liver. *Nature*, **2014**, 514, 380-4	50.4	521
6	KRAS and YAP1 converge to regulate EMT and tumor survival. *Cell*, **2014**, 158, 171-84	56.2	482
5	Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. *Nature Biotechnology*, **2014**, 32, 551-3	44.5	694
4	Response and resistance to NF-B inhibitors in mouse models of lung adenocarcinoma. *Cancer Discovery*, **2011**, 1, 236-47	24.4	104
3	Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. *Nature*, **2007**, 445, 656-60	50.4	1786
2	Tissue-specific Genome Editing in vivo by MicroRNA-repressible Anti-CRISPR Proteins		1
1	Programming large target genomic deletion and concurrent insertion via a prime editing-based method: PEDAR		1